Evidence map›Paper›PMID 25275131›Full record

ArticleJournal of virology2014

Vaccine-induced CD107a+ CD4+ T cells are resistant to depletion following AIDS virus infection.

Kazutaka Terahara, Hiroshi Ishii, Takushi Nomura, Naofumi Takahashi, Akiko Takeda, Teiichiro Shiino, Yasuko Tsunetsugu-Yokota, Tetsuro Matano

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Env-independent protection of intrarectal SIV challenge by vaccine induction of Gag/Vif-specific CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Article
  7. Article
  8. Vaccines · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Precursors of human CD4Science immunology · 2018
    Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kazutaka TeraharaDepartment of Immunology, National Institute of Infectious Diseases, Tokyo, Japan.
Hiroshi IshiiAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Takushi NomuraAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Naofumi TakahashiAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Akiko TakedaAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Teiichiro ShiinoAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Yasuko Tsunetsugu-YokotaDepartment of Immunology, National Institute of Infectious Diseases, Tokyo, Japan.
Tetsuro MatanoAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan The Institute of Medical Science, The University of Tokyo, Tokyo, Japan tmatano@nih.go.jp.
National Institute of Infectious Diseases · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledCD4(+) T-cell responses are crucial for effective antibody and CD8(+) T-cell induction following virus infection. However, virus-specific CD4(+) T cells can be preferential targets for human immunodeficiency virus (HIV) infection. HIV-specific CD4(+) T-cell induction by vaccination may thus result in enhancement of virus replication following infection. In the present study, we show that vaccine-elicited CD4(+) T cells expressing CD107a are relatively resistant to depletion in a macaque AIDS model. Comparison of virus-specific CD107a, macrophage inflammatory protein-1β, gamma interferon, tumor necrosis factor alpha, and interleukin-2 responses in CD4(+) T cells of vaccinated macaques prechallenge and 1 week postchallenge showed a significant reduction in the CD107a(-) but not the CD107a(+) subset after virus exposure. Those vaccinees that failed to control viremia showed a more marked reduction and exhibited significantly higher viral loads at week 1 than unvaccinated animals. Our results indicate that vaccine-induced CD107a(-) CD4(+) T cells are depleted following virus infection, suggesting a rationale for avoiding virus-specific CD107a(-) CD4(+) T-cell induction in HIV vaccine design. IMPORTANCE: Induction of effective antibody and/or CD8(+) T-cell responses is a principal vaccine strategy against human immunodeficiency virus (HIV) infection. CD4(+) T-cell responses are crucial for effective antibody and CD8(+) T-cell induction. However, virus-specific CD4(+) T cells can be preferential targets for HIV infection. Here, we show that vaccine-induced virus-specific CD107a(-) CD4(+) T cells are largely depleted following infection in a macaque AIDS model. While CD4(+) T-cell responses are important in viral control, our results indicate that virus-specific CD107a(-) CD4(+) T-cell induction by vaccination may not lead to efficient CD4(+) T-cell responses following infection but rather be detrimental and accelerate viral replication in the acute phase. This suggests that HIV vaccine design should avoid virus-specific CD107a(-) CD4(+) T-cell induction. Conversely, this study found that vaccine-induced CD107a(+) CD4(+) T cells are relatively resistant to depletion following virus challenge, implying that induction of these cells may be an alternative approach toward HIV control.

Indexed as

AIDS VaccinesAnimalsCD4 Lymphocyte CountCD4-Positive T-LymphocytesHIVLymphocyte SubsetsLysosomal-Associated Membrane Protein 1Macaca mulattaAIDS VaccinesLysosomal-Associated Membrane Protein 1

Identifiers

PMID25275131
PMCPMC4249136
OpenAlexW1978284967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.